S-1 · primary offering
Issued 2026
Proposed maximum
Shares registered
- Filed
- Effective
Sector: Pharmaceutical PreparationsIndustry: Medical - PharmaceuticalsCountry: USExchange: Nasdaq
DilutionScan read 22 of Retension Pharmaceuticals, Inc.'s SEC filings and found 3 warrant series, 2 convertibles, 1 S-1 registration and 1 completed offering on file for RTSN. The latest dilution event on file is an offering on Oct 13, 2026. Analysis updated Nov 13, 2026.
Raise routes on file: no active ATM, effective shelf, issuer S-1 or active equity line in the filings read · latest dilution event 35 days ago
The dominant contractual driver and its mechanism, then each further driver ranked.
Oct 13, 2026 · Offering
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
From $29.99/mo. Signal8 Pro is $49/mo, or $40.67/mo billed yearly ($488/yr)
Shares outstanding, potential dilution and cash over time
Issued 2026
Proposed maximum
Shares registered
Shares Underlying
Exercise Price
Shares Underlying
Exercise Price
Shares Underlying
Exercise Price
Principal
Conversion Price
Principal
Conversion Price
Issued 2026
Gross proceeds
Price per share
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
From $29.99/mo. Signal8 Pro is $49/mo, or $40.67/mo billed yearly ($488/yr)
DilutionScanEvery instrument in full · From $29.99/mo
Covered companies in Medical - Pharmaceuticals. All tickers A to Z